GlobeNewswire: Celladon Corporation Contains the last 10 of 52 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T11:23:38ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2016/03/21/821870/0/en/Celladon-Announces-Results-of-Special-Meeting.html?f=22&fvtc=4&fvtv=20896Celladon Announces Results of Special Meeting2016-03-21T20:05:00Z<![CDATA[SAN DIEGO, March 21, 2016 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN) announced today that, based upon the final vote count certified by the independent inspector of elections for the special meeting of stockholders held March 21, 2016, stockholders approved all of the merger-related proposals, including: (i) the merger and issuance of Celladon common stock pursuant to the Agreement and Plan of Merger and Reorganization, dated November 18, 2015, by and among Celladon, Celladon Merger Sub, Inc. and Eiger BioPharmaceuticals, Inc., (ii) a 1-for-15 reverse stock split of Celladon common stock and (iii) changing the name of the Company from “Celladon Corporation” to “Eiger BioPharmaceuticals, Inc.”  The reverse stock split will become effective immediately following the close of trading on March 22, 2016, and the closing of the merger and name change are expected to occur immediately thereafter.   The consolidated common shares for the combined company are expected to commence trading on The NASDAQ Global Market under the symbol "EIGR" on March 23, 2016.]]>https://www.globenewswire.com/news-release/2016/03/09/818420/0/en/ISS-and-Glass-Lewis-Recommend-Celladon-Corporation-Shareholders-Vote-FOR-Proposed-Merger.html?f=22&fvtc=4&fvtv=20896ISS and Glass Lewis Recommend Celladon Corporation Shareholders Vote "FOR" Proposed Merger2016-03-09T21:05:00Z<![CDATA[SAN DIEGO, March 09, 2016 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN) announced today that Institutional Shareholder Services ("ISS") and Glass Lewis & Co., two of the leading independent U.S. proxy advisory firms, have both recommended that the Company's shareholders vote "FOR" the proposals in its proxy statement for the special meeting of shareholders to be held on March 21, 2016.  The special meeting will be held at 9:00 a.m., local time, on March 21, 2016 at 12255 El Camino Real, Suite 300, San Diego, California 92130.  Celladon stockholders of record as of the close of business on February 12, 2016 are entitled to receive notice of, and to vote at, the special meeting.    ]]>https://www.globenewswire.com/news-release/2016/02/10/809618/0/en/Celladon-Sets-Date-for-Special-Meeting-of-Stockholders.html?f=22&fvtc=4&fvtv=20896Celladon Sets Date for Special Meeting of Stockholders2016-02-10T21:57:33Z<![CDATA[SAN DIEGO, Feb. 10, 2016 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN) announced today it has set a date for a special meeting of its stockholders to vote on matters related to the proposed merger with Eiger BioPharmaceuticals, Inc. ]]>https://www.globenewswire.com/news-release/2015/11/19/788589/0/en/Eiger-BioPharmaceuticals-and-Celladon-Corporation-Sign-Merger-Agreement.html?f=22&fvtc=4&fvtv=20896Eiger BioPharmaceuticals and Celladon Corporation Sign Merger Agreement2015-11-19T03:36:05Z<![CDATA[--Celladon-Eiger Proposed Merger Creates a Biopharmaceutical Company With Diverse Portfolio of Four Novel Drug Development Programs Addressing Orphan Diseases----Concurrent Financing of $39.5 Million From Investor Syndicate--]]>https://www.globenewswire.com/news-release/2015/08/11/759865/10145656/en/Celladon-Reports-Second-Quarter-2015-Financial-Results.html?f=22&fvtc=4&fvtv=20896Celladon Reports Second Quarter 2015 Financial Results2015-08-11T20:15:00Z<![CDATA[SAN DIEGO, Aug. 11, 2015 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), today announced financial results for the quarter ended June 30, 2015 and recent corporate updates.]]>https://www.globenewswire.com/news-release/2015/06/26/747748/10139820/en/Celladon-Corporation-Provides-Business-Update.html?f=22&fvtc=4&fvtv=20896Celladon Corporation Provides Business Update2015-06-26T10:00:00Z<![CDATA[
SAN DIEGO, June 26, 2015 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), today confirmed its plans to suspend further research or development of its MYDICAR (AAV1/SERCA2a) program and its other pre-clinical programs including the Stem Cell Factor (mSCF) gene therapy and SERCA2b small molecule programs.]]>https://www.globenewswire.com/news-release/2015/06/01/740829/10136622/en/Celladon-Corporation-Announces-Strategic-Direction-Following-Review-of-CUPID2-Data.html?f=22&fvtc=4&fvtv=20896Celladon Corporation Announces Strategic Direction Following Review of CUPID2 Data2015-06-01T11:00:00Z<![CDATA[-- Company to Seek Acquisition or Partnership --
-- Wedbush PacGrow Healthcare Securities Retained as Exclusive Financial Advisor --]]>https://www.globenewswire.com/news-release/2015/05/14/736082/10134587/en/Celladon-Reports-First-Quarter-2015-Financial-Results.html?f=22&fvtc=4&fvtv=20896Celladon Reports First Quarter 2015 Financial Results2015-05-14T20:30:00Z<![CDATA[SAN DIEGO, May 14, 2015 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced financial results for the quarter ended March 31, 2015 and recent corporate updates.]]>https://www.globenewswire.com/news-release/2015/04/26/728336/10130767/en/Celladon-Reports-Negative-Results-for-CUPID2-Trial-of-MYDICAR-R-in-Advanced-Heart-Failure.html?f=22&fvtc=4&fvtv=20896Celladon Reports Negative Results for CUPID2 Trial of MYDICAR(R) in Advanced Heart Failure2015-04-26T20:40:56Z<![CDATA[
- ]]>https://www.globenewswire.com/news-release/2015/03/30/720278/10126884/en/Celladon-Reports-Fourth-Quarter-and-Year-End-2014-Financial-Results-and-Recent-Highlights.html?f=22&fvtc=4&fvtv=20896Celladon Reports Fourth Quarter and Year-End 2014 Financial Results and Recent Highlights2015-03-30T20:05:00Z<![CDATA[CUPID2 Topline Data Release on Track for Late April]]>